ADAG

Announcements

Nothing here yet

Daily updates

Nothing here yet

FDA designations

Nothing here yet

News

• Adagene receives NMPA clearance for the investigational new drug application for ADG138, a novel HER2xCD3 double-masked bispecific T-cell engagerSep 22, 2026
• Third Arc Bio selected its first lead candidate under the amended collaboration with Adagene to develop masked CD3 T-cell engagers using SAFEbody technologySep 10, 2026
• Adagene achieved a collaboration milestone with Exelixis advancing SAFEbody antibody-drug conjugate candidatesSep 9, 2026
• Updated Phase 1b/2 data of muzastotug plus KEYTRUDA showed improved durability in colorectal cancerApr 2, 2026
• Adagene receives FDA Fast Track designation for Muzastotug (ADG126)Dec 16, 2025